Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 6,533 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Subject Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults

NCT00532610
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
GSK189075
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 22, 2026, 5:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lung HIV Microbiome Project (Michigan Site)

NCT02392182
View directory record Official record
Conditions
Healthy Participants, Tobacco Use Disorder, Human Microbiome
Interventions
Fiberoptic bronchoscopy
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 16, 2016 · Synced Oct 22, 2026, 5:08 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00605059
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I]AV94
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2010 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers

NCT02955459
View directory record Official record
Conditions
Bacterial Infections
Interventions
VNRX-5133, Placebo
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers

NCT01011296
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-04427429
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers

NCT01711762
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0973
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years

NCT07670377
View directory record Official record
Conditions
Malaria, Falciparum
Interventions
Midazolam (MDZ), GSK3772701
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Synera in Healthy Volunteers

NCT01602757
View directory record Official record
Conditions
Healthy
Interventions
Synera
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Lu AG06474 in Healthy Young Men

NCT05003687
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06474, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants

NCT03990519
View directory record Official record
Conditions
Healthy
Interventions
JNJ-26366821, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 22, 2026, 5:08 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

NCT06980428
View directory record Official record
Conditions
Healthy Participants, Dyslipidemia
Interventions
AZD4954, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

NCT01740609
View directory record Official record
Conditions
Healthy
Interventions
Placebo, PF-06342674 Dose A, PF-06342674 Dose B, PF-06342674 Dose C, PF-06342674 Dose D, PF-06342674 Dose E, PF-06342674 Dose F, PF-06342674 Dose G, PF-06342674 Dose H, PF-06342674 Dose I, PF-06342674 Dose J
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional

Safety and Immunogenicity of an HIV Vaccine in Normal Adult Volunteers

NCT00083330
View directory record Official record
Conditions
Healthy, HIV Infections
Interventions
VRC-HIVADV014-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 44 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

NCT00575367
View directory record Official record
Conditions
Bacterial Infections, Eye Infections
Interventions
AzaSite (azithromycin ophthalmic solution), Vigamox (moxifloxacin hydrochloride ophthalmic solution)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

NCT00827034
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Warfarin, Dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About Whether BAY H006689 Causes an Allergic Reaction When Applied as a Topical Gel in Healthy Participants

NCT06415019
View directory record Official record
Conditions
Pain, Healthy Volunteers
Interventions
Naproxen (BAYH006689), Placebo Gel, A solution of 0.9% Saline
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis

NCT00432900
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
[(11)C]PBR28
Radiation
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects

NCT03541564
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Healthy Participants
Interventions
BMS-986165, Moxifloxacin, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects

NCT04793295
View directory record Official record
Conditions
Healthy Subjects
Interventions
MT-7117
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects

NCT01565681
View directory record Official record
Conditions
Pharmacokinetics of ASKP1240, Healthy Volunteers
Interventions
ASP1240, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Cryotherapy on Cerebral Hemodynamics Within Healthy Subjects

NCT03185507
View directory record Official record
Conditions
Cryotherapy Effect, Oxygen Deficiency
Interventions
CryoHelmet
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 25 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 22, 2026, 5:08 AM EDT
Terminated No phase listed Observational

Clinical Autonomic Disorders: A Training Protocol

NCT02154009
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Pseudopheochromocytoma, Healthy Volunteers, Neurocardiogenic Syncope, Postural Tachycardia Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
2 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resistant Starch Blend Gastrointestinal Impact

NCT03983772
View directory record Official record
Conditions
Quality of Life, Health, Subjective
Interventions
RS blend, Placebo
Dietary Supplement · Other
Lead sponsor
Metagenics, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Gig Harbor, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

18F-LY3950321-01 Biodistribution and Safety Study

NCT05775601
View directory record Official record
Conditions
Diagnostic Agent Adverse Reaction, Radiation Exposure
Interventions
18F-LY3950321, PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 22, 2026, 5:08 AM EDT